The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation

Weiguo Dong, Christine M. Embury, Yaman Lu, Sarah M. Whitmire, Bhagyalaxmi Dyavarshetty, Harris A. Gelbard, Howard Eliot Gendelman, Tomomi Kiyota

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein kinase (MAPK) pathways in Alzheimer's disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK signaling that include p38 MAPK and c-Jun amino-terminal kinase (JNK). However, whether MLK-MAPK pathways affect Aβ-mediated neuroinflammation is unknown. To this end, we investigated if URMC-099, a brain-penetrant small-molecule MLK type 3 inhibitor, can modulate Aβ trafficking and processing required for generating AD-associated microglial inflammatory responses. Methods: Aβ1-42 (Aβ42) and/or URMC-099-treated murine microglia were investigated for phosphorylated mitogen-activated protein kinase kinase (MKK)3, MKK4 (p-MKK3, p-MKK4), p38 (p-p38), and JNK (p-JNK). These pathways were studied in tandem with the expression of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Gene expression of the anti-inflammatory cytokines, IL-4 and IL-13, was evaluated by real-time quantitative polymerase chain reaction. Aβ uptake and expression of scavenger receptors were measured. Protein trafficking was assessed by measures of endolysosomal markers using confocal microscopy. Results: Aβ42-mediated microglial activation pathways were shown by phosphorylation of MKK3, MKK4, p38, and JNK and by expression of IL-1β, IL-6, and TNF-α. URMC-099 modulated microglial inflammatory responses with induction of IL-4 and IL-13. Phagocytosis of Aβ42 was facilitated by URMC-099 with up-regulation of scavenger receptors. Co-localization of Aβ and endolysosomal markers associated with enhanced Aβ42 degradation was observed. Conclusions: URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel disease-modifying AD therapy.

Original languageEnglish (US)
Article number184
JournalJournal of Neuroinflammation
Volume13
Issue number1
DOIs
StatePublished - Jul 11 2016

Fingerprint

Amyloid
Mitogen-Activated Protein Kinases
Scavenger Receptors
Alzheimer Disease
Phosphotransferases
Interleukin-13
Interleukin-1
Interleukin-4
Interleukin-6
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
MAP Kinase Kinase 3
MAP Kinase Kinase 4
Cytokines
JNK Mitogen-Activated Protein Kinases
Microglia
p38 Mitogen-Activated Protein Kinases
Protein Transport
URMC-099
mitogen-activated protein kinase kinase kinase 11

Keywords

  • Alzheimer's disease
  • Amyloid-β
  • Endolysosomal pathway
  • Microglia
  • Mixed-lineage kinase 3
  • Phagocytosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Immunology
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Dong, W., Embury, C. M., Lu, Y., Whitmire, S. M., Dyavarshetty, B., Gelbard, H. A., ... Kiyota, T. (2016). The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. Journal of Neuroinflammation, 13(1), [184]. https://doi.org/10.1186/s12974-016-0646-z

The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. / Dong, Weiguo; Embury, Christine M.; Lu, Yaman; Whitmire, Sarah M.; Dyavarshetty, Bhagyalaxmi; Gelbard, Harris A.; Gendelman, Howard Eliot; Kiyota, Tomomi.

In: Journal of Neuroinflammation, Vol. 13, No. 1, 184, 11.07.2016.

Research output: Contribution to journalArticle

Dong, Weiguo ; Embury, Christine M. ; Lu, Yaman ; Whitmire, Sarah M. ; Dyavarshetty, Bhagyalaxmi ; Gelbard, Harris A. ; Gendelman, Howard Eliot ; Kiyota, Tomomi. / The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. In: Journal of Neuroinflammation. 2016 ; Vol. 13, No. 1.
@article{46459160e3224da99f051835279cb184,
title = "The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation",
abstract = "Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein kinase (MAPK) pathways in Alzheimer's disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK signaling that include p38 MAPK and c-Jun amino-terminal kinase (JNK). However, whether MLK-MAPK pathways affect Aβ-mediated neuroinflammation is unknown. To this end, we investigated if URMC-099, a brain-penetrant small-molecule MLK type 3 inhibitor, can modulate Aβ trafficking and processing required for generating AD-associated microglial inflammatory responses. Methods: Aβ1-42 (Aβ42) and/or URMC-099-treated murine microglia were investigated for phosphorylated mitogen-activated protein kinase kinase (MKK)3, MKK4 (p-MKK3, p-MKK4), p38 (p-p38), and JNK (p-JNK). These pathways were studied in tandem with the expression of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Gene expression of the anti-inflammatory cytokines, IL-4 and IL-13, was evaluated by real-time quantitative polymerase chain reaction. Aβ uptake and expression of scavenger receptors were measured. Protein trafficking was assessed by measures of endolysosomal markers using confocal microscopy. Results: Aβ42-mediated microglial activation pathways were shown by phosphorylation of MKK3, MKK4, p38, and JNK and by expression of IL-1β, IL-6, and TNF-α. URMC-099 modulated microglial inflammatory responses with induction of IL-4 and IL-13. Phagocytosis of Aβ42 was facilitated by URMC-099 with up-regulation of scavenger receptors. Co-localization of Aβ and endolysosomal markers associated with enhanced Aβ42 degradation was observed. Conclusions: URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel disease-modifying AD therapy.",
keywords = "Alzheimer's disease, Amyloid-β, Endolysosomal pathway, Microglia, Mixed-lineage kinase 3, Phagocytosis",
author = "Weiguo Dong and Embury, {Christine M.} and Yaman Lu and Whitmire, {Sarah M.} and Bhagyalaxmi Dyavarshetty and Gelbard, {Harris A.} and Gendelman, {Howard Eliot} and Tomomi Kiyota",
year = "2016",
month = "7",
day = "11",
doi = "10.1186/s12974-016-0646-z",
language = "English (US)",
volume = "13",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation

AU - Dong, Weiguo

AU - Embury, Christine M.

AU - Lu, Yaman

AU - Whitmire, Sarah M.

AU - Dyavarshetty, Bhagyalaxmi

AU - Gelbard, Harris A.

AU - Gendelman, Howard Eliot

AU - Kiyota, Tomomi

PY - 2016/7/11

Y1 - 2016/7/11

N2 - Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein kinase (MAPK) pathways in Alzheimer's disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK signaling that include p38 MAPK and c-Jun amino-terminal kinase (JNK). However, whether MLK-MAPK pathways affect Aβ-mediated neuroinflammation is unknown. To this end, we investigated if URMC-099, a brain-penetrant small-molecule MLK type 3 inhibitor, can modulate Aβ trafficking and processing required for generating AD-associated microglial inflammatory responses. Methods: Aβ1-42 (Aβ42) and/or URMC-099-treated murine microglia were investigated for phosphorylated mitogen-activated protein kinase kinase (MKK)3, MKK4 (p-MKK3, p-MKK4), p38 (p-p38), and JNK (p-JNK). These pathways were studied in tandem with the expression of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Gene expression of the anti-inflammatory cytokines, IL-4 and IL-13, was evaluated by real-time quantitative polymerase chain reaction. Aβ uptake and expression of scavenger receptors were measured. Protein trafficking was assessed by measures of endolysosomal markers using confocal microscopy. Results: Aβ42-mediated microglial activation pathways were shown by phosphorylation of MKK3, MKK4, p38, and JNK and by expression of IL-1β, IL-6, and TNF-α. URMC-099 modulated microglial inflammatory responses with induction of IL-4 and IL-13. Phagocytosis of Aβ42 was facilitated by URMC-099 with up-regulation of scavenger receptors. Co-localization of Aβ and endolysosomal markers associated with enhanced Aβ42 degradation was observed. Conclusions: URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel disease-modifying AD therapy.

AB - Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein kinase (MAPK) pathways in Alzheimer's disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK signaling that include p38 MAPK and c-Jun amino-terminal kinase (JNK). However, whether MLK-MAPK pathways affect Aβ-mediated neuroinflammation is unknown. To this end, we investigated if URMC-099, a brain-penetrant small-molecule MLK type 3 inhibitor, can modulate Aβ trafficking and processing required for generating AD-associated microglial inflammatory responses. Methods: Aβ1-42 (Aβ42) and/or URMC-099-treated murine microglia were investigated for phosphorylated mitogen-activated protein kinase kinase (MKK)3, MKK4 (p-MKK3, p-MKK4), p38 (p-p38), and JNK (p-JNK). These pathways were studied in tandem with the expression of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Gene expression of the anti-inflammatory cytokines, IL-4 and IL-13, was evaluated by real-time quantitative polymerase chain reaction. Aβ uptake and expression of scavenger receptors were measured. Protein trafficking was assessed by measures of endolysosomal markers using confocal microscopy. Results: Aβ42-mediated microglial activation pathways were shown by phosphorylation of MKK3, MKK4, p38, and JNK and by expression of IL-1β, IL-6, and TNF-α. URMC-099 modulated microglial inflammatory responses with induction of IL-4 and IL-13. Phagocytosis of Aβ42 was facilitated by URMC-099 with up-regulation of scavenger receptors. Co-localization of Aβ and endolysosomal markers associated with enhanced Aβ42 degradation was observed. Conclusions: URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel disease-modifying AD therapy.

KW - Alzheimer's disease

KW - Amyloid-β

KW - Endolysosomal pathway

KW - Microglia

KW - Mixed-lineage kinase 3

KW - Phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=84978998200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978998200&partnerID=8YFLogxK

U2 - 10.1186/s12974-016-0646-z

DO - 10.1186/s12974-016-0646-z

M3 - Article

C2 - 27401058

AN - SCOPUS:84978998200

VL - 13

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 184

ER -